Phase 3 PNH Clinical Trials

4 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–4 of 4 trials

Recruiting

Phase 3

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH

Novartis Pharmaceuticals12 enrolled13 locationsNCT06934967

Recruiting

Phase 3

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

PNHExtravascular HemolysisParoxysmal nocturnal hemoglobinuria

Alexion Pharmaceuticals, Inc.6 enrolled4 locationsNCT06449001

Recruiting

Phase 3

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Paroxysmal nocturnal haemoglobinuria (PNH)

Wuhan Createrna Science and Technology Co., Ltd66 enrolled2 locationsNCT06932744

Recruiting

Phase 2Phase 3

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria, PNH

Wuhan Createrna Science and Technology Co., Ltd120 enrolled1 locationNCT06933914